The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
AQUIPTA (Allergan Australia Pty Ltd)
Product name
AQUIPTA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
211 (255 working days)
Active ingredients
atogepant
Registration type
NCE/NBE
Indication
AQUIPTA is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month